Labiotech.eu

News and Trends 5 Nov 2015

Damn, that was BIO-Europe 2015 in Munich!

We are now back in Berlin after three (intense) days at BIO-Europe 2015 in Munich. It was definitely a great fair. We covered the event with articles and videos to give you a live insight, (almost) as if you were there. Everything is below 😉 Day 1 : EU’s biggest Biotech Fair, BIO-Europe 2015, […]

November 5, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2015

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

And here is the fourth interview I did at BIO-Europe 2015. This time, I am with Andre Hoekema, top-executive from the belgian Biotech success-story, Galapagos. We recently covered extensively the 400-employee company based north of Bruxelles. It made the biggest IPO ever by a EU Biotech on the NASDAQ, raising 270 million euros. It also recently had […]

November 4, 2015 - 1 minutemin - By Philip Hemme

News and Trends 4 Nov 2015

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers: The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to […]

November 4, 2015 - 3 minutesmins - By Philip Hemme

peter Llewellyn Davies medigene interview

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Second interview of BIO-Europe 2015. This time, it’s a British company from Cambridge (UK): F-star. This morning we spoke with their CBO Jane Dancer. F-star is developing bi-specific antibodies for immuno-oncology and inflammatory disease. It has raised a total of 38 million euros from top EU VCs. Jane Dancer’s business tenure within the field is […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

History of Biotech: 25 Years of The Human Genome Project

The birth of the Human Genome Project was now 25 years ago (woah!)…What was the HGP’s significance to biotech? What? The Human Genome Project (HGP) was an international effort with a primary goal; to sequence the entire genetic code of a whole organism (Humans…). It today remains the largest ever world collaborative project, which thrust the […]

November 3, 2015 - 5 minutesmins - By Marie Godar

News and Trends 3 Nov 2015

Potato Plastics! Biodegradable Plastics from Potato Waste

An Italian company specialized in the production of environmentally sustainable materials has created its Minverv PHAs. These are ‘green’ biopolymers with the same thermo-mechanical properties of the substances that make up the traditional plastics, but are instead 100% biodegradable. The goal was to create a plastic that does not pollute the environment and Bio-On, company […]

November 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 Nov 2015

To IPO or not to IPO when you are a Biotech company? #BIO-Europe 2015

This is the second conference I attended at BIO-Europe. This is an interesting topic when you look at the different EU Biotech companies delaying their IPOs. The conference gathered four big speakers, among them Olivier Litzka, partner from Edmond de Rothschild (part of our TOP 15 EU VCs), Konrad Glund, the CEO of Berlin-based Probiodrug, […]

November 3, 2015 - 4 minutesmins - By Philip Hemme

interview simon moroney labiotech bio europe

News and Trends 2 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

BIO-Europe is also a great opportunity to meet with top people from EU’s Biotech ecosystem. I had the chance to interview Simon Moroney, the CEO and one of the founders of MorphoSys (part of our top 9 EU-based billion euros Biotechs). The Munich-based company was founded in 1992 and now counts +-350 employees for a market […]

November 2, 2015 - 1 minutemin - By Philip Hemme

News and Trends 2 Nov 2015

How Big can be Small in Biotech – #BIO-Europe 2015 Keynote

As usual at BIO-Europe, the fair starts with an opening keynote, this time with speakers from Merck Healthcare, MedImmune/AstraZeneca and Baxalta. The keynote is basically a discussion between high-level speakers, akin to the talk which took place in Paris during March, when Antoine Papiernik (the prominent European VC from Sofinnova) led a panel discussion with […]

November 2, 2015 - 5 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Damn, that was BIO-Europe 2015 in Munich!

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

History of Biotech: 25 Years of The Human Genome Project

Potato Plastics! Biodegradable Plastics from Potato Waste

To IPO or not to IPO when you are a Biotech company? #BIO-Europe 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

How Big can be Small in Biotech – #BIO-Europe 2015 Keynote

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!